DexCom Financials - Benzinga

DexCom Inc

DXCMNASDAQ

Trade with Public

Trade with Public

$92.16

-0.18-0.19%

마지막 업데이트: Aug 24, 10:58 AM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

DexCom Financials

DexCom (DXCM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est

DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.

Benzinga Newsdesk

PRO
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.61 by 14.75 percent. This is a 45.83 percent increase over earnings of $0.48 per share from the same

Benzinga Newsdesk

Diabetes Tech Player DexCom Lays Out 2030 Growth Vision

DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share Buyback

Vandana Singh

PRO
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est

2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following

Benzinga Newsdesk

PRO
DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 75 percent increase over earnings of $0.32 per share from the same period

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved